疾病特异性eQTL筛查揭示AGXT2在非酒精性脂肪性肝病中的抗纤维化作用
该研究对125名韩国人(83例经活检证实的NAFLD患者和42名无NAFLD者)进行疾病特异性eQTL筛查,鉴定出仅在NAFLD组出现的eQTL,并在162名NAFLD患者中复制。发现AGXT2 rs2291702非参考等位基因纯合子NAFLD患者AGXT2表达降低,敲低AGXT2加重肝细胞损伤和鼠肝纤维化,过表达则减轻纤维化和脂肪变性。
要点
- AGXT2 rs2291702非参考等位基因纯合与NAFLD患者AGXT2表达降低相关。
- 敲低AGXT2加重棕榈酸负荷肝细胞死亡和NAFLD小鼠肝纤维化。
- 过表达AGXT2减轻小鼠肝纤维化和脂肪变性。
核心结论
- AGXT2在NAFLD中具有新的分子作用,其rs2291702变异以基因型依赖方式影响AGXT2表达并保护肝脏免受纤维化。
- 疾病特异性eQTL筛查是发现NAFLD遗传因子的有效工具。
研究设计与样本
- 研究纳入125名韩国人(83例经活检证实的NAFLD患者和42名无NAFLD者),对21,272个转录本和3,234,941个基因分型及填充的单核苷酸多态性进行eQTL分析。
- 筛选仅在NAFLD组检测到的eQTL(NAFLD-eQTL),并在162名韩国NAFLD患者中复制。
- 使用HepG2细胞、原代肝细胞和NAFLD小鼠模型验证候选eQTL的功能。
主要发现
- NAFLD特异性eQTL筛查得到242个位点。
- 在NAFLD患者中,rs2291702非参考等位基因纯合者AGXT2表达低于相同基因型的无NAFLD个体(p = 4.79 × 10-6)。
- 该变化在162名额外个体中复制,合并245例NAFLD患者和42名对照的p值为8.05 × 10-8。
- 敲低AGXT2通过增加内质网应激诱导棕榈酸过载的肝细胞死亡,并加重NAFLD饮食诱导的小鼠肝纤维化。
- 过表达AGXT2减轻肝纤维化和脂肪变性。
临床怎么用
- AGXT2及其rs2291702变异可能作为NAFLD纤维化的遗传标志物和治疗靶点。
- 疾病特异性eQTL筛查策略可用于发现其他基因型依赖的NAFLD相关基因。
局限性
- 研究基于韩国人群,结果外推需谨慎。
- 功能验证主要使用细胞和小鼠模型,人体直接证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) poses an increasing clinical burden. Genome-wide association studies have revealed a limited contribution of genomic variants to the disease, requiring alternative but robust approaches to identify disease-associated variants and genes. We carried out a disease-specific expression quantitative trait loci (eQTL) screen to identify novel genetic factors that specifically act on NAFLD progression on the basis of genotype. METHODS: We recruited 125 Korean patients (83 with biopsy-proven NAFLD and 42 without NAFLD) and performed eQTL analyses using 21,272 transcripts and 3,234,941 genotyped and imputed single nucleotide polymorphisms. We then selected eQTLs that were detected only in the NAFLD group, but not in the control group (i.e., NAFLD-eQTLs). An additional cohort of 162 Korean individuals with NAFLD was used for replication. The function of the selected eQTL toward NAFLD development was validated using HepG2, primary hepatocytes and NAFLD mouse models. RESULTS: The NAFLD-specific eQTL screening yielded 242 loci. Among them, AGXT2, encoding alanine-glyoxylate aminotransferase 2, displayed decreased expression in patients with NAFLD homozygous for the non-reference allele of rs2291702, compared to no-NAFLD individuals with the same genotype (p = 4.79 × 10-6). This change was replicated in an additional 162 individuals, yielding a combined p value of 8.05 × 10-8 from a total of 245 patients with NAFLD and 42 controls. Knockdown of AGXT2 induced palmitate-overloaded hepatocyte death by increasing endoplasmic reticulum stress, and exacerbated NAFLD diet-induced liver fibrosis in mice, while overexpression of AGXT2 attenuated liver fibrosis and steatosis. CONCLUSIONS: We identified a new molecular role for AGXT2 in NAFLD. Our overall approach will serve as an efficient tool for uncovering novel genetic factors that contribute to liver steatosis and fibrosis in patients with NAFLD. LAY SUMMARY: Elucidating causal genes for non-alcoholic fatty liver disease (NAFLD) has been challenging due to limited tissue availability and the polygenic nature of the disease. Using liver and blood samples from 125 Korean individuals (83 with NAFLD and 42 without NAFLD), we devised a new analytic method to identify causal genes. Among the candidates, we found that AGXT2-rs2291702 protects against liver fibrosis in a genotype-dependent manner with the potential for therapeutic interventions. Our approach enables the discovery of causal genes that act on the basis of genotype.
引用
- Yoo T, Joo SK, Kim HJ, et al. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. J Hepatol. 2021. PMID: 33892010. doi:10.1016/j.jhep.2021.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。